Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:6502:0:b0:439:fcfb:30e with SMTP id x2csp1240259wru; Thu, 26 Mar 2026 07:30:49 -0700 (PDT) X-Received: by 2002:a05:6214:2e4a:b0:899:ac2b:6ddc with SMTP id 6a1803df08f44-89cc4b354bcmr99873046d6.62.1774535448232; Thu, 26 Mar 2026 07:30:48 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1774535448; cv=none; d=google.com; s=arc-20240605; b=U1RTxmyNaL8ec4OWF/eayfNw0jvX47XtCSMNS7fVnjxvJxnwxkgfl73ZAz4BPx80SB iPqnu+e5qVi7KHmeJ5wDOVc6P7Ge9Q8igY8YPUuORJTAdiXXM3VKhYj0y8x61sxZzZDR IDSLpwSlQn1QlkBf++ZITGrirYCYb7m/nrQLBf0oRGZXh86xfQShdPImfghYj7P36EkI VdbypxT/x7aKLPQSZxABoTb7i6vC1XI7f612EciIXDFIXDTxMFssWQucoyrgEgB5DWhy WN5wt7czOEeHVEnsQZOYzSNDqIXZKtFHwC3cIRSFER12rYHVZGI64zTigpSnv25bWTFD tL8w== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=BCRc3pR9nEuX8xdIu6jKRL213n+BktSvCCrS594UUaw=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=CwQXJCPKd68qyhbsDP8O05+Usumz4EXdO8g7sSoSKLHedUSkaXJvlGGFn+MwY/mx3x Hswn3GEgt1WHoCOVDhqbiqyBfJGE+zg2IW/Vz0H0XM/+mntLNlBByuUmEEwYM0idA9Sb F8ZJCpUNNlYCAIw22V9Mjj7DDBJtU2vMf0HWTnpZHdequk4NjG8w0IN1a/s1W0lGVWeL 4HtYVcqgDgZ243S5xjxFTS6cQJLWlqhIm8Ep6JoEiXBrTGJry5ecOEGxqVhC4ImztdHZ XqRpkzLZhZSfHPnisi5tsSLjNZ30XUGa/lifh2de631MhPuXkXYZcUXrvOLvAxGT4lam 6/7w==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=iOuuivEw; dkim=pass header.i=@mailgun.org header.s=mg header.b=Nl6tqbW7; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.8 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v58.v5375b7fa.use4.send.mailgun.net (v58.v5375b7fa.use4.send.mailgun.net. [159.112.244.8]) by mx.google.com with UTF8SMTPS id 6a1803df08f44-89cd5ad01f7si33063336d6.489.2026.03.26.07.30.47 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Thu, 26 Mar 2026 07:30:48 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.8 as permitted sender) client-ip=159.112.244.8; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=iOuuivEw; dkim=pass header.i=@mailgun.org header.s=mg header.b=Nl6tqbW7; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.8 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1774535447; x=1774542647; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=BCRc3pR9nEuX8xdIu6jKRL213n+BktSvCCrS594UUaw=; b=iOuuivEwpK0Lf9PgxKsmi+txytAffgYxmVhExzqcixIMdziVcdRw+spMPH+dCVOaYU6kcsaPnguZc+4nU0kxK15p8UORrew/c8CvfNlfr1AAD8o1UtTCZ5P9sWg6amilp+nKGoriK9seGY5PjKO2S9OheyJOI2oDSrNt4vEpl8U= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1774535447; x=1774542647; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=BCRc3pR9nEuX8xdIu6jKRL213n+BktSvCCrS594UUaw=; b=Nl6tqbW7qicA/MtFSu9Y2F486rDkAhEEl/8Ru0mqJDx/xwjT96wNWlSULouBIHdYU5RWhqwSrKh5+Enw/ObQwi5N7vvZKF1pvrtTWjWnA5hxthyf+4aH+7ePIY9W05oiGzhw3WQDdmhZmb24JidwrbFK5wvUgql4X1MDbXVMp80= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by d8c7c960e4ae0a3aee89db81a7a45f8390a380ab789fb31a6f75aefdb230671d with HTTP id 69c5431630bb068c5bd907a2; Thu, 26 Mar 2026 14:30:46 GMT X-Mailgun-Sending-Ip: 159.112.244.8 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="20dcbb9d8dee77aa49365c81c3b2bccf3005b2b233539584a2050642af82" Subject: =?UTF-8?q?GW501516_(Cardarine)_=E2=80=94_Full_Research_Breakdown:_Mechani?= =?UTF-8?q?sms,_Cancer_Data,_and_What_the_Human_Trials_Actually_Show?= From: Derek from Peptide Price To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260326143040.3.94c25ea1643e28a2@mg-d0.substack.com> Date: Thu, 26 Mar 2026 14:30:40 +0000 Feedback-Id: post-192206879:cat-post:pub-3365367:substack Sender: Derek from Peptide Price References: In-Reply-To: Reply-To: Derek from Peptide Price List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1774535446875", "is_freemail": "true", "post_audience": "everyone", "post_id": "192206879", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --20dcbb9d8dee77aa49365c81c3b2bccf3005b2b233539584a2050642af82 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/gw501516-ca= rdarine-full-research For research purposes only. Not for human consumption. What Is Cardarine? Cardarine (also known as GW501516 or GW1516) is a synthetic compound that a= ctivates something called the PPAR=CE=B4 receptor (peroxisome proliferator-= activated receptor delta). This receptor controls genes involved in energy = metabolism =E2=80=94 specifically how your body burns fat and uses fuel. It was originally developed to treat high cholesterol and metabolic disorde= rs, and early human clinical trials showed very promising results. However,= animal studies revealed a serious cancer concern, and all further pharmace= utical research was abandoned. Despite this, it remains widely used in the = fitness community for fat loss and endurance. It is not a SARM =E2=80=94 it has zero activity at the androgen receptor. I= t is on the WADA prohibited list, which confirms it has measurable performa= nce effects. (Kintz et al., 2021) What Does Cardarine Actually Do? Here=E2=80=99s a straightforward breakdown of the evidence-based effects: Fat Loss & Metabolism Stimulates fatty acid beta-oxidation =E2=80=94 your body burns stored fat f= or fuel more efficiently (Grewal et al., 2016) Promotes fat loss in a caloric deficit Reduces liver fat content =E2=80=94 one human trial showed a 20% reduction = in just two weeks at 10mg/day (Park et al., 2021) Reverses metabolic abnormalities in obese and pre-diabetic research subject= s (Bianchi et al., 2023) Blood Work / Lipid Parameters At 10mg/day in human clinical trials, cardari= ne produced measurable improvements (Bianchi et al., 2023; Park et al., 202= 1): HDL (=E2=80=9Dgood cholesterol=E2=80=9D) increased up to 16.9% LDL reduced 7=E2=80=9323% Triglycerides reduced 17=E2=80=9330% Fasting insulin reduced ~11% Free fatty acids reduced ~20% These improvements showed up in as little as two weeks. Endurance & Performance Increases stamina and endurance capacity (Narkar et al., 2008) Shown to increase Type I (slow-twitch, endurance) muscle fibers in animal m= odels (Wang et al., 2004) Improves how skeletal and cardiac muscle uses energy (Li et al., 2015) Other Notable Effects Improves insulin sensitivity (Grewal et al., 2016) Anti-inflammatory effects (systemic, brain, lungs, kidneys, liver) (Bianchi= et al., 2023) Antioxidant and anti-hypertensive properties (Bianchi et al., 2023) Cardiovascular protective effects (Wall et al., 2016) Wound healing and collagen synthesis support in skin (Bianchi et al., 2023) Neuroprotective effects (Bianchi et al., 2023) PPAR=CE=B4 activation shown to increase MMP-9 expression, which degrades IG= F-1 binding protein 3 and increases free IGF-1 receptor activation in endot= helial progenitor cells (Han et al., 2013) The Cancer Question =E2=80=94 What the Science Actually Says This is the most important section, and it requires nuance. There are curre= ntly 27 published studies examining cardarine=E2=80=99s relationship with c= ancer. Here=E2=80=99s how they break down (Bianchi et al., 2023): 19 studies show cardarine has pro-cancer effects (accelerates tumor growth) 8 studies show cardarine may actually inhibit certain cancers and promote c= ancer cell death That 19:8 split should not be dismissed. But here=E2=80=99s the critical co= ntext most people miss: The animal studies used genetically modified mice =E2=80=94 animals specifi= cally bred to be highly susceptible to cancer. These are not normal, health= y organisms. Additionally, some studies administered cardarine for up to 10= 4 weeks, which represents more than half the animal=E2=80=99s entire lifesp= an (Bianchi et al., 2023). The dose matters enormously. In the animal models, cancer formation began a= t doses that =E2=80=94 when converted to human equivalent doses using valid= ated conversion methodology =E2=80=94 are not far from what the fitness com= munity commonly uses (Janhavi et al., 2022): 2mg/kg in animal models (early cancer signals) =E2=86=92 human equivalent: = ~8=E2=80=9319mg/day 10mg/kg in animal models (confirmed tumor growth) =E2=86=92 human equivalen= t: ~40=E2=80=9397mg/day A 20=E2=80=9330mg/day research protocol sits uncomfortably close to that lo= wer end. The human clinical trials tell a different story =E2=80=94 but only at low = doses. At doses of 2.5mg, 5mg, and 10mg daily for up to 12 weeks, human sub= jects showed (Bianchi et al., 2023; Park et al., 2021): No significant adverse health effects No changes in liver or muscle enzymes No changes in kidney markers Generally well tolerated The evidence suggests 10mg/day for up to 12 weeks is the dose with the most= human safety data behind it. It is also worth noting that early research flagged a potential concern aro= und platelet function =E2=80=94 one animal model study found PPAR=CE=B2/=CE= =B4 agonism may inhibit platelet activation and adhesion, suggesting a poss= ible bleeding risk at certain doses, though this was not observed in the hu= man trials (Ali et al., 2009). Additionally, one animal study found cardari= ne may increase sphingomyelin synthesis, raising a potential atherosclerosi= s concern =E2=80=94 again not replicated in human data (Bianchi et al., 202= 3). Practical Considerations The dose with the most human safety data: 10mg/day, up to 12 weeks Going beyond this increases cancer risk without a proportional benefit payo= ff =E2=80=94 especially when there are other fat loss tools available. Cardarine + Carnitine: Why You Need Both One of the most overlooked points: cardarine increases fatty acid beta-oxid= ation, which depletes your carnitine stores (Grewal et al., 2016). Many res= earch subjects report cardarine appears to =E2=80=9Cstop working=E2=80=9D a= round weeks 4=E2=80=936. The likely reason is carnitine depletion, not comp= ound tolerance. To keep fat burning running efficiently, consider pairing with: Oral L-Carnitine L-Tartrate: 1,000mg before fasted cardio + another 500=E2= =80=931,000mg before training Injectable L-Carnitine: 500mg before fasted cardio =E2=80=94 also has some = nootropic properties in research models One important note: do not combine cardarine with Mildronate in research pr= otocols. They have completely opposing mechanisms. Mildronate inhibits carn= itine synthesis while cardarine increases the demand for it. These two comp= ounds work against each other directly. Detection Times Relevant for any research subject under testing protocols (Kintz et al., 20= 21): Cardarine=E2=80=99s main metabolites (GW sulfoxide and GW sulphone) have ex= tremely slow elimination rates GW sulphone detectable in urine up to 40 days after a single 15mg dose GW sulfoxide detectable up to 25 days after a single dose With repeated dosing over multiple weeks, metabolite accumulation extends d= etection significantly =E2=80=94 potentially 5+ months Cardarine can also be detected in hair samples Estimated half-life of cardarine: approximately 16=E2=80=9324 hours based o= n available data (Kintz et al., 2021). Before Running This Compound in Research Given the cancer data =E2=80=94 even accounting for the limitations of the = animal models =E2=80=94 the responsible approach before any cardarine resea= rch protocol includes (Bianchi et al., 2023): Full blood panel including cancer markers at baseline Review of family history for cancer predisposition Consider genetic testing for known cancer risk genes Repeat blood work post-cycle If cancer is already present or suspected in the research subject, cardarin= e is off the table entirely. The in vitro human cancer cell line data consi= stently shows it accelerates existing cancer cell proliferation regardless = of dose (Bianchi et al., 2023). Bottom Line The research data on cardarine is genuinely compelling =E2=80=94 the lipid,= fat loss, and endurance findings are hard to dismiss (Narkar et al., 2008;= Wang et al., 2004; Park et al., 2021). But the cancer signal from the anim= al data is equally real, and the doses commonly used in research protocols = (20=E2=80=9330mg+) exceed what has been formally studied for safety in huma= ns (Bianchi et al., 2023). The most defensible protocol based on current evidence: 10mg/day, 12 weeks = maximum, with carnitine supplementation, and blood work before and after. The risk/reward calculation is one every researcher has to make for themsel= ves =E2=80=94 but it should be made with the full picture in front of you, = not just the upside. References Wang, Y.X. et al. (2004). Regulation of muscle fiber type and running endur= ance by PPAR=CE=B4. PLOS Biology, 2(10):e294. Narkar, V.A. et al. (2008). AMPK and PPAR=CE=B4 agonists are exercise mimet= ics. Cell, 134(3):405-15. Ali, F.Y. et al. (2009). PPAR=CE=B2/=CE=B4 agonists modulate platelet funct= ion via a mechanism involving PPAR receptors and specific association/repre= ssion of PKC=CE=B1. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(= 11):1871-3. Han, J.K. et al. (2013). PPAR=CE=B4 activates endothelial progenitor cells = to induce angio-myogenesis through MMP-9-mediated IGF-1 paracrine networks.= European Heart Journal, 34(23):1755-65. Li, S. et al. (2015). Exercise Pills: At the Starting Line. Trends in Pharm= acological Sciences, 36(12):906-917. Grewal, A.S. et al. (2016). Recent Updates on PPAR=CE=B4 Agonists for the T= reatment of Metabolic Syndrome. Journal of Medicinal Chemistry, 12(1):3-21. Wall, C.E. et al. (2016). Nuclear receptors and AMPK: can exercise mimetics= cure diabetes? Journal of Molecular Endocrinology, 57(1):R49-58. Kintz, P. et al. (2021). PPAR=CE=B4 Agonist and SARM Abuse: Clinical, Analy= tical and Biological Data in a Case Involving GW1516 and MK2866. Toxics, 9(= 10):251. Park, J. et al. (2021). Cardarine (GW501516) Effects on Improving Metabolic= Syndrome. Journal of Health, Sports, and Kinesiology, 2(2):22-27. Janhavi, P. et al. (2022). DoseCal: a virtual calculator for dosage convers= ion between human and different animal species. Archives of Physiology and = Biochemistry, 128(2):426-430. Bianchi, V.E. et al. (2023). GW501516 (Cardarine): Pharmacological and Clin= ical Effects. Genetics & Molecular Medicine, 5(1):1-12. All compounds discussed are for research purposes only. Not for human consu= mption. This post is educational and does not constitute medical advice. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNakl3TmpnM09Td2lhV0YwSWpveE56YzBOV= E0xTkRRMkxDSmxlSEFpT2pFNE1EWXdOekUwTkRZc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5Lk5XSEVFQ3pacjNMNXBXdjEtd0dCV29qTjJ= nb1E0UzVnQ2lIV1hZSVVTRTAiLCJwIjoxOTIyMDY4NzksInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc0NTM1NDQ2LCJleHAiOjIwOTAxMTE0NDYsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.53OJ4D97M7-NRojQs-k9MDOsEjNVGZ-r5X0WbZB= 0pqY? --20dcbb9d8dee77aa49365c81c3b2bccf3005b2b233539584a2050642af82 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable GW501516 (Cardarine) = 212; Full Research Breakdown: Mechanisms, Cancer Data, and What the Human T= rials Actually Show3D""
For research purposes only.
͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­
<= tr>
=
 

For research p= urposes only. Not for human consumption.

What Is= Cardarine?

Cardarine (also known as GW50151= 6 or GW1516) is a synthetic compound that activates something called the PPARδ receptor (peroxisome proliferator-ac= tivated receptor delta). This receptor controls genes involved in energy me= tabolism — specifically how your body burns fat and uses fuel.=

It was originally developed to treat high cholesterol and = metabolic disorders, and early human clinical trials showed very promising = results. However, animal studies revealed a serious cancer concern, and all= further pharmaceutical research was abandoned. Despite this, it remains wi= dely used in the fitness community for fat loss and endurance.

It is not a SARM — it has ze= ro activity at the androgen receptor. It is on the WADA prohibited list, wh= ich confirms it has measurable performance effects. (Kintz et al= =2E, 2021)

3D""
Upgrade to paid

What D= oes Cardarine Actually Do?

Here’s a straight= forward breakdown of the evidence-based effects:

Fa= t Loss & Metabolism

  • Stimulates fatty a= cid beta-oxidation — your body burns stored fat for fuel more efficie= ntly (Grewal et al., 2016)

  • Promotes fat loss in a caloric deficit

    • Reduces liver fat con= tent — one human trial showed a 20% reduction in just two weeks at 10= mg/day (Park et al., 2021)

  • Reverses metabolic abnormalities in obese a= nd pre-diabetic research subjects (Bianchi et al., 2023)

Blood Work / Lipid Parameters At 10mg/day in human clinical trials, cardarine produced measurable impro= vements (Bianchi et al., 2023; Park et al., 2021):

  • HDL (”good cholesterol”) increased up to= 16.9%

  • LDL reduce= d 7–23%

  • Tri= glycerides reduced 17–30%

  • Fasting insulin reduced ~11%

  • Free fatty acids reduced ~20%

These improvements showed up in as little as two weeks.

Endurance & Performance

  • I= ncreases stamina and endurance capacity (Narkar et al., 2008)

  • <= p style=3D"color: rgb(54,55,55);line-height: 26px;margin-bottom: 0;box-sizi= ng: border-box;padding-left: 4px;font-size: 16px;margin: 0;">Shown to= increase Type I (slow-twitch, endurance) muscle fibers in animal models (Wang et al., 2004)

  • Improves how skeletal and cardiac muscle uses energy= (Li et al., 2015)

Other = Notable Effects

  • Improves insulin sensitivi= ty (Grewal et al., 2016)

  • Anti-inflammatory effects (systemic, brain, l= ungs, kidneys, liver) (Bianchi et al., 2023)

  • Antioxidant and anti-hype= rtensive properties (Bianchi et al., 2023)

  • Cardiovascular protective e= ffects (Wall et al., 2016)

  • Wound healing and collagen synthesis suppor= t in skin (Bianchi et al., 2023)

  • Neuroprotective effects (B= ianchi et al., 2023)

  • PPARδ activation shown to increase MMP-9 expression, wh= ich degrades IGF-1 binding protein 3 and increases free IGF-1 receptor acti= vation in endothelial progenitor cells (Han et al., 2013)

The Cancer Question — What the Science= Actually Says

This is the most important se= ction, and it requires nuance. There are currently 27 published studies exa= mining cardarine’s relationship with cancer. Here’s how they br= eak down (Bianchi et al., 2023):

  • 19 studies show cardarine has pro-cancer effec= ts (accelerates tumor growth)

  • 8 studies show cardarine may act= ually inhibit certain cancers and promote cancer cell death

    • =

That 19:8 split should not be dismissed. But here’s= the critical context most people miss:

The animal = studies used genetically modified mice — animals speci= fically bred to be highly susceptible to cancer. These are not normal, heal= thy organisms. Additionally, some studies administered cardarine for up to = 104 weeks, which represents more than half the animal’s entire lifesp= an (Bianchi et al., 2023).

The dose= matters enormously. In the animal models, cancer formation = began at doses that — when converted to human equivalent doses using = validated conversion methodology — are not far from what the fitness = community commonly uses (Janhavi et al., 2022):

  • 2mg/kg in animal models (early cancer signals)<= /strong> → human equivalent: ~8–19mg/day

    • <= li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">

    10mg/kg in animal = models (confirmed tumor growth) → human equivalent: ~4= 0–97mg/day

A 20–30mg/day resea= rch protocol sits uncomfortably close to that lower end.

The human clinical trials tell a different story — but only at = low doses. At doses of 2.5mg, 5mg, and 10mg daily for up to = 12 weeks, human subjects showed (Bianchi et al., 2023; Park et a= l., 2021):

    No significant adverse healt= h effects

  • No chan= ges in liver or muscle enzymes

  • No changes in kidney markers

  • Generally well tolerated

It is also worth noting that early research flagged a= potential concern around platelet function — one animal model study = found PPARβ/δ agonism may inhibit platelet activation and adhesio= n, suggesting a possible bleeding risk at certain doses, though this was no= t observed in the human trials (Ali et al., 2009). Ad= ditionally, one animal study found cardarine may increase sphingomyelin syn= thesis, raising a potential atherosclerosis concern — again not repli= cated in human data (Bianchi et al., 2023).

Practical Considerations

The dose= with the most human safety data: 10mg/day, up to 12 weeks

Going beyond this increases cancer risk without a proportional ben= efit payoff — especially when there are other fat loss tools availabl= e.

Cardarine + Carnitine: Why You Need Both

One of the most overlooked points: cardarine increa= ses fatty acid beta-oxidation, which depletes your carnitine stores = (Grewal et al., 2016). Many research subjects report cardari= ne appears to “stop working” around weeks 4–6. The likely= reason is carnitine depletion, not compound tolerance.

To keep fat burning running efficiently, consider pairing with:

  • Oral L-Carnitine L-Tartrate: 1,000mg bef= ore fasted cardio + another 500–1,000mg before training

  • Injectable L-= Carnitine: 500mg before fasted cardio — also has some = nootropic properties in research models

    • One important note: do not combine cardarine with Mildro= nate in research protocols. They have completely opposing me= chanisms. Mildronate inhibits carnitine synthesis while cardarine increases= the demand for it. These two compounds work against each other directly.

    Detection Times

    = Relevant for any research subject under testing protocols (Kintz= et al., 2021):

      Cardarine’s mai= n metabolites (GW sulfoxide and GW sulphone) have extremely slow eliminatio= n rates

    • G= W sulphone detectable in urine up to 40 days<= /strong> after a single 15mg dose

    • GW sulfoxide detectabl= e up to 25 days after a single dose

    • With repeated= dosing over multiple weeks, metabolite accumulation extends detection sign= ificantly — potentially 5+ months

      • Cardarine can also be = detected in hair samples

    = Estimated half-life of cardarine: approximately 16–24 hours bas= ed on available data (Kintz et al., 2021).

    Before Running This Compound in Research

    Given the cancer data — even accounting for the limitations of the= animal models — the responsible approach before any cardarine resear= ch protocol includes (Bianchi et al., 2023):

    • Full blood panel including cancer markers at baseline

      <= /li>

    • Review of family hist= ory for cancer predisposition

    • Consider genetic testing for known cancer risk genes

      • <= li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">

      Repeat blood work post-cyc= le

    If cancer is already present or suspecte= d in the research subject, cardarine is off the table entirely. The in vitr= o human cancer cell line data consistently shows it accelerates existing ca= ncer cell proliferation regardless of dose (Bianchi et al., 2023= ).

    Bottom Line

    Th= e research data on cardarine is genuinely compelling — the lipid, fat= loss, and endurance findings are hard to dismiss (Narkar et al.= , 2008; Wang et al., 2004; Park et al., 2021). But the cancer si= gnal from the animal data is equally real, and the doses commonly used in r= esearch protocols (20–30mg+) exceed what has been formally studied fo= r safety in humans (Bianchi et al., 2023).

    = The most defensible protocol based on current evidence: 10mg/day, 12 weeks maximum, with carnitine supplementation, and blood wor= k before and after.

    The risk/reward calculation is= one every researcher has to make for themselves — but it should be m= ade with the full picture in front of you, not just the upside.

    References

    • Wang, Y.X. et al. = (2004). Regulation of muscle fiber type and running endurance by PPARδ= =2E PLOS Biology,= 2(10):e294.

    • Narkar, V.A. et al. (2008). = AMPK and PPARδ agonists are exercise mimetics. Cell, 134(3):405-15.

    • Ali, F.Y. et al. (2009). PPARβ/δ agonists modulat= e platelet function via a mechanism involving PPAR receptors and specific a= ssociation/repression of PKCα. Arteriosclerosis, Thrombosis= , and Vascular Biology, 29(11):1871-3.

    • Han, J.K. et al. (2013). PPA= Rδ activates endothelial progenitor cells to induce angio-myogenesis t= hrough MMP-9-mediated IGF-1 paracrine networks. European Heart J= ournal, 34(23):1755-65.

    • Li, S. et al. (2015). Exercise Pills: At the= Starting Line. Trends in Pharmacological Sciences, 3= 6(12):906-917.

    • Grewal, A.S. et al. (2016). Recent Updates on PPARδ Agonist= s for the Treatment of Metabolic Syndrome. Journal of Medicinal = Chemistry, 12(1):3-21.

    • Wall, C.E. et al. (2016). Nuclear receptors a= nd AMPK: can exercise mimetics cure diabetes? Journal of Molecul= ar Endocrinology, 57(1):R49-58.

    • Kintz, P. et al. (2021). PPARδ = Agonist and SARM Abuse: Clinical, Analytical and Biological Data in a Case = Involving GW1516 and MK2866. Toxics, 9(10):251.

    • Park, J. = et al. (2021). Cardarine (GW501516) Effects on Improving Metabolic Syndrome= =2E Journal of Health, Sport= s, and Kinesiology, 2(2):22= -27.

    • Janhavi, P. et al. (2022). DoseCal: a virtual calculator for dosage conver= sion between human and different animal species. Archives of Phy= siology and Biochemistry, 128(2):426-430.

    • Bianchi, V.E. et al. (2023= ). GW501516 (Cardarine): Pharmacological and Clinical Effects. G= enetics & Molecular Medicine, 5(1):1-12.

      • <= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">All compounds discussed are for research purposes only. Not= for human consumption. This post is educational and does not constitute me= dical advice.

      Upgrade to = paid

    You're= currently a free subscriber to upgrade your s= ubscription.

    Upgrade to paid

     
    =
    <= /table>
    3D""Share
     
     
    =
    = Like
    3D""Comment=
    3D""Restack
     

    © 2026 D= erek Pruski
    548 Market Street PMB 72296, San Francisco, CA 94104 =
    Unsubscribe

    3D"Start

    3D"" --20dcbb9d8dee77aa49365c81c3b2bccf3005b2b233539584a2050642af82--